Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7952W HIGH $7.61
Volume
1.23 M
Value Traded
2.31 M
Short % Float
6.37%
-1.49%Week
-57.39%1 Month
-66.55%3 Month
-56.64%6 Month
-57.97%5 Year
-77.79%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
118.18 M
EPS (TTM)
-1.09
P/E Ratio
-
Ent. Value
-49.41 M
Total Shares
59.40 M
Float Shares
31.31 M
Insiders
47.28%
Institutions
47.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FHTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Foghorn Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Foghorn Therapeutics Inc.
342Total events
9Upcoming
42Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Program DiscontinuationFHD-909DiscontinuedCorporate
Foghorn and Lilly decide not to advance FHD-909 into clinical development expansion phase
▼Program DiscontinuationCorporate
Collaboration will not advance the Selective SMARCA2 degrader program
●Pipeline PrioritizationCorporate
Focus resources on wholly owned pipeline including EP300 degrader, immunology and inflammation program, CBP degrader and induced proximity platform
▼Trial DiscontinuedFHD-909DiscontinuedTrial
Foghorn and Lilly decide not to advance FHD-909 into expansion phase
●Trial InitiationFHD-909DiscontinuedTrial
FHD-909 Phase 1 dose-escalation trial advancing as planned
non-small cell lung cancersource ↗
◆Oral PresentationPresentation
Fireside Chat at Goldman Sachs 47th Annual Global Healthcare Conference 2026
◆Oral PresentationPresentation
Foghorn management to present at TD Cowen 7th Annual Oncology Innovation Summit
◆Oral PresentationPresentation
Foghorn management to present at 2026 Stifel Virtual Targeted Oncology Forum
◆Oral PresentationPresentation
Foghorn management to participate in one-on-one meetings at H.C. Wainwright 4th Annual Bioconnect Investor Conference
▲Enrollment UpdateFHD-909DiscontinuedTrial
Phase 1 trial enrollment progressing well and on track
SMARCA4-mutant non-small cell lung cancersource ↗
◆Oral PresentationPresentation
Oral presentation on towards new cancer medicines with degraders of chromatin regulatory proteins
cancersource ↗
◆Poster PresentationFHT-171Presentation
Poster presentation on preclinical characterization of FHT-171, a first-in-class degrader targeting CBP
CBP-dependent solid tumorssource ↗
◆Oral PresentationFHD-909DiscontinuedPresentation
Oral presentation on leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
SMARCA4-mutant cancerssource ↗
▲Oral PresentationEP300Presentation
Oral presentation at AACR 2026: Targeting chromatin regulatory proteins in hematologic malignancies (EP300 degrader)
multiple myelomasource ↗
▲Poster PresentationFHT-171Presentation
Poster presentation at AACR 2026: Preclinical characterization of FHT-171, a first-in-class degrader targeting CBP
CBP-dependent solid tumors (ER+ breast cancer)source ↗
▲Poster PresentationEP300Presentation
Poster presentation at AACR 2026: Preclinical evaluation of selective and potent EP300 degraders
hematologic malignancies (multiple myeloma)source ↗
◆Poster PresentationPresentation
Poster presentation on identification of first-in-class selective ARID1B degraders
ARID1A-mutant tumorssource ↗
◆Poster PresentationEP300Presentation
Poster presentation on leveraging selective degradation of CBP and EP300 for potent anti-cancer activity
cancersource ↗
◆Oral PresentationPresentation
Oral presentation on targeting chromatin regulatory proteins in hematologic malignancies
hematologic malignanciessource ↗
◆Poster PresentationEP300Presentation
Poster presentation on preclinical evaluation of selective and potent EP300 degraders
hematologic malignanciessource ↗
◆Oral PresentationPresentation
Foghorn Therapeutics management presentation at Guggenheim Emerging Outlook: Biotech Summit
▼Equity OfferingCorporate
Raised $50 million in equity financing with BVF Partners, Deerfield Management, Flagship Pioneering and a leading biotech mutual fund
▲Enrollment UpdateFHD-909DiscontinuedTrial
Phase 1 dose-escalation trial of FHD-909 advancing as planned, enrollment progressing well
SMARCA4-mutant cancers (NSCLC)source ↗
▼Equity OfferingCorporate
Raised $50 million in equity financing with BVF Partners, Deerfield Management, Flagship Pioneering and a leading biotech mutual fund
▲Poster PresentationFHD-909DiscontinuedPresentation
Preclinical combination data with anti-PD-1 antibody presented at AACR 2026
SMARCA4-mutant cancerssource ↗
▲Poster PresentationFHT-171Presentation
Preclinical data for Selective CBP degrader CBPd-171 presented at AACR 2026
ER+ breast cancersource ↗
▲Poster PresentationEP300Presentation
Preclinical data for Selective EP300 degraders presented at AACR 2026
Multiple myelomasource ↗
▲Poster PresentationPresentation
Preclinical data for Selective ARID1B degraders presented at AACR 2026
ARID1A-mutated cancerssource ↗
◆Development Candidate NominationPreclinical
Development candidate for selective ARID1B degrader
ARID1A mutant cancers (e.g., ovarian, endometrial, colorectal)source ↗
▲First Patient DosedFHD-909DiscontinuedTrial
FHD-909 Phase 1 dose escalation trial ongoing in SMARCA4-mutated cancers
SMARCA4-mutated cancerssource ↗
◆R&D DayPresentation
Virtual investor event to review pipeline updates for Selective ARID1B, Selective CBP and Selective EP300 degrader programs
◆Oral PresentationPresentation
Presentation of key development updates for Selective ARID1B degrader at TPD Summit
endometrial, gastric, and bladder cancerssource ↗
▲Poster PresentationPresentation
Preclinical data for Selective ARID1B degrader presented at TPD and Induced Proximity Summit (earlier this week)
solid tumorssource ↗
●IND Enabling CompletePreclinical
Selective CBP degrader on track for non-GLP toxicology studies in Q4 2025
EP300-mutant cancers, ER+ breast cancersource ↗
◆Timing GuidanceEP300Presentation
Program update expected for Selective EP300 degrader in Q4 2025
Hematological malignancies and prostate cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How FHTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-22 | FHT-171 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$256M
Pipeline Value
Fair Value
Valuation Signal
1
Drugs Scored
2.1x
rNPV / MCap
Top 41%
Micro Cap(rank 270 of 658)
Percentile Rank
Foghorn Therapeutics Inc. faces pipeline headwinds (39/100), with $1.0B risk-adjusted pipeline value, led by FHD-286 in Small Cell Lung Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FHD-286 Small moleculeNCT07551635 | Small Cell Lung Cancer | Phase 2 | NOT YET_RECRUITING | 20 | Jan 31, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every FHTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FHD-286 | relapsed and refractory AML | Phase 1 | 2024-12-16 | objective clinical responses were observed by standard response criteriaRead More | Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in coRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GOTTSCHALK ADRIANDirector, Officer (Chief Executive Officer) | Disposition | -59,208 240,792 held | $0.00 | 04/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FHTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.7 % (-22.2 %) | 28.51 M | 5.84 M |
FHTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FHTX ranks across every disease it competes in
Competitive Position is a premium feature
See how FHTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFHTX News
FHTX▼ -18.2%on this news· ran to -45% by day 3
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics has decided not to advance FHD-909 and the Selective SMARCA2 degrader program following a review of clinical data. The company will focus on its proprietary pipeline, including several new programs, while reducing its workforce by 40% to extend its cash runway into 2029. The CEO expressed disappointment over the clinical results but emphasized the commitment to advancing other promising programs.
Read more →FHTX▲ +14.1%on this news· ran to +35% by day 3
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics has provided an update on its financials and corporate progress for the second quarter of 2026. The Phase 1 dose-escalation trial for FHD-909, targeting non-small cell lung cancer, is proceeding as scheduled. Additionally, the company is advancing selective EP300 degraders aimed at treating multiple myeloma and other hematological malignancies, with an IND submission planned for 2027.
Read more →FHTXFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Foghorn Therapeutics Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company, focused on advancing gene expression correction technologies, will feature a fireside chat by CEO Adrian Gottschalk on June 9, 2026. Additionally, Foghorn will engage in one-on-one meetings at the event. The conference highlights Foghorn's commitment to addressing serious diseases, particularly in oncology.
Read more →FHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Foghorn Therapeutics Inc. will participate in three investor conferences in May 2026, including the H.C. Wainwright 4th Annual Bioconnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. CEO Adrian Gottschalk will present at the Stifel Virtual Targeted Oncology Forum and the Cowen Summit, highlighting the company's innovative approach to oncology through its Gene Traffic Control platform.
Read more →FHTX▼ -10.3%on this newsshared move
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics provided a financial and corporate update, highlighting progress in its clinical trials, particularly FHD-909 for NSCLC patients with SMARCA4 mutations. The company reported promising preclinical data for its selective CBP and EP300 degraders, with IND filings anticipated in 2027. Despite a net loss increase, Foghorn maintains a strong financial position with substantial cash reserves.
Read more →FHTXFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics presented new preclinical data at the 2026 AACR Annual Meeting, highlighting promising results for their Selective SMARCA2 inhibitor FHD-909 in combination with an anti-PD-1 antibody, demonstrating tumor regression and lasting immune memory in animal models. The data also showcased the efficacy and safety of their Selective CBP and EP300 degrader programs in treating difficult cancers. Notably, the Selective CBP degrader FHT-171 showed strong activity in heavily pretreated ER+ breast cancer, while EP300 degraders outperformed existing treatments in multiple myeloma. Overall, the presentations underscored Foghorn's advancements in developing targeted therapies for cancer.
Read more →FHTXFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics announced new preclinical data for its selective SMARCA2 inhibitor FHD-909 and degrader programs at the 2026 AACR Annual Meeting. The data suggests potential expansion opportunities for FHD-909 in combination with anti-PD-1 antibodies for treating SMARCA4-mutant lung cancer. Additionally, the company showcased progress in its selective CBP, EP300, and ARID1B degrader programs, highlighting their promise in treating challenging cancers.
Read more →FHTXFoghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Foghorn Therapeutics has provided a financial update alongside a strategic outlook for 2025 and 2026. The company highlighted the progress of its lead candidate, FHD-909, a treatment for SMARCA4-mutant non-small cell lung cancer, which is currently in Phase 1 trials. Additionally, Foghorn announced a successful $50 million financing round, significantly improving its financial position and extending operational runways. Upcoming IND-enabling studies for additional programs targeting various cancers are slated for 2026.
Read more →FHTXFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. The company is focused on developing innovative treatments for serious diseases through its Gene Traffic Control platform. A webcast of the TD Cowen presentation will be available on their website for 90 days.
Read more →FHTXFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics has appointed Ryan Maynard as Chief Financial Officer, effective February 23, 2026. With over 25 years of experience in the biopharmaceutical sector, Maynard aims to enhance the company's financial strategy and operational performance. His previous roles include CFO at Cara Therapeutics, where he led significant financial transactions. His expertise is expected to support Foghorn's growth and development of novel therapies.
Read more →FHTXFoghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York. The company focuses on developing innovative medicines to correct abnormal gene expression, particularly in oncology. A webcast of their presentation will be available for 30 days following the event.
Read more →FHTX▼ -5.5%on this news· ran to -17% by day 3
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Foghorn Therapeutics has successfully closed a $50 million registered direct financing at a 30% premium. The offering included the sale of over 2 million shares at $6.71 each, with additional warrants for future purchases. Key investors included BVF Partners and Deerfield Management. The funds will support the company's development of novel medicines targeting gene expression.
Read more →FHTXFoghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Foghorn Therapeutics has successfully raised $50 million in equity financing, which is expected to close on January 13, 2026. The funds will support ongoing development of its cancer treatment pipeline, including a Phase 1 trial of FHD-909 targeting SMARCA4-mutant non-small cell lung cancer. The company also highlighted progress in its Selective CBP and EP300 degrader programs, both of which are projected to be IND-ready in 2026. With a strong balance sheet showing $208.9 million in cash and equivalents, Foghorn aims to continue strategic investments in its therapeutic programs through at least the first half of 2028.
Read more →FHTXFoghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Foghorn Therapeutics will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, FL. The company's management will host a fireside chat on December 4 at 9:10 a.m. EST. Foghorn focuses on developing innovative treatments targeting gene expression abnormalities, particularly in oncology.
Read more →FHTX▲ +13.3%on this news· ran to +25% by day 3
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics provided a financial and corporate update for Q3 2025, highlighting the progress of its FHD-909 Phase 1 trial targeting SMARCA4-mutated cancers, particularly non-small cell lung cancer (NSCLC). The company reported a strong cash position of $180.3 million, ensuring operational stability into 2028. Additionally, Foghorn is advancing multiple selective degrader programs aimed at various cancers, although the departure of CFO Kristian Humer raises some concerns about leadership continuity.
Read more →FHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics announced its participation in three upcoming investor conferences, including the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. The company focuses on developing innovative treatments for serious diseases through its Gene Traffic Control platform, particularly in oncology. Presentations will be available via webcast on their website.
Read more →FHTXFoghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Foghorn Therapeutics has announced advancements in its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader has shown potential in treating various solid tumors, while the Selective CBP degrader is set for non-GLP toxicology studies in Q4 2025. The Selective EP300 degrader demonstrates efficacy in hematological malignancies, marking significant progress for the company.
Read more →FHTXFoghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn Therapeutics has announced key updates regarding its Selective ARID1B degrader program, which will be presented at the 8th Annual TPD and Induced Proximity Summit. The findings suggest the program could become a new treatment option for patients with endometrial, gastric, and bladder cancers. Additionally, a virtual investor event will provide further insights into the company's ongoing projects.
Read more →About Foghorn Therapeutics Inc.
Headquarters500 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next FHTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime